Pharmaceuticals Global On demand · 24-48h

Global Biopharmaceutical Logistic Market Strategic Research Report

Global Biopharmaceutical Logistic Market Strategic Research …
$3,500 USD
Market Research Reports
Strategic Research Report
Global Biopharmaceutical Logistic Market
$44.04B2025
8.1%CAGR
2032Forecast
Market Research Reports · Global
Market Research Reports Intelligence Series

By Type: Cold Chain Logistics, Non-cold Chain Logistics

By Application: Ground Shipping, Sea Shipping, Air Shipping

Regional Forecast: Asia Pacific, Latin America, MEA, Europe, North America

Key Players: Deutsche Post DHL, Kuehne + Nagel, UPS, McKesson, FedEx, Nippon Express, Cencora, SF Express, CMA CGM, DSV, Kerry Logistics, CH Robinson, Air Canada Cargo, Sinopharm Group, Shanghai Pharma, CR Pharma, Jointown Logistics, BioLife Solutions, OOCL Logistics, Shengsheng Pharmaceutical Cold Chain

Region: Global
Formats: PDF, Excel, Word & PowerPoint
Base year: 2025 · forecast to 2032
Length: 130 pages
Market size 2025
$44.04B
Billion USD
Forecast CAGR
8.1%
2025-2032
Forecast 2032
$76B
Projected
Régions
5
Asia Pacific · Latin America · MEA · Europe · North America

Vue d'ensemble

Scope of the Report

The global Biopharmaceutical Logistic market size is predicted to grow from US$ 44,038 million in 2025 to US$ 76,068 million in 2032; it is expected to grow at a CAGR of 8.1% from 2026 to 2032.

Biopharmaceutical Logistics refers to a specialized logistics system that manages temperature-controlled transportation, storage, and supply chain coordination throughout the entire lifecycle of biopharmaceutical products, including development, manufacturing, distribution, and clinical use. Its primary objective is to ensure the integrity, safety, and regulatory compliance of high-value biologics such as vaccines, monoclonal antibodies, and cell and gene therapies. This system relies on advanced cold chain technologies (ranging from 2–8°C to ultra-low temperatures such as -80°C), real-time monitoring systems, and global distribution networks to enable high-standard delivery from production sites to healthcare providers. With the rapid growth of the biopharmaceutical industry and increasing complexity of global supply chains, biopharmaceutical logistics has evolved from a traditional transportation function into a critical infrastructure integrating technology, services, and compliance, playing a vital role in enabling commercialization and globalization of innovative therapies.The average gross profit margin of this product is 35%.

Driven by the rapid expansion of the global biopharmaceutical industry and the accelerated commercialization of innovative therapies, biopharmaceutical logistics is experiencing strong structural growth. Products such as vaccines, monoclonal antibodies, and cell and gene therapies require strict temperature control and handling conditions, transforming cold chain logistics from a supporting function into a core capability. Governments worldwide are strengthening regulatory frameworks for pharmaceutical distribution, promoting standardization and compliance. According to corporate disclosures and financial analyses, major pharmaceutical companies are expanding globally, significantly increasing demand for high-quality logistics services. Meanwhile, the integration of digital technologies and IoT is enhancing visibility and traceability across the supply chain, further elevating industry value.Despite strong growth prospects, the industry faces several challenges. Biopharmaceutical products are highly sensitive to temperature variations, and any deviation during transportation may compromise product integrity, placing stringent demands on logistics providers. Cross-border transportation involves complex regulatory compliance across multiple jurisdictions, increasing operational complexity and costs. In addition, cold chain infrastructure remains underdeveloped in certain emerging markets, limiting industry expansion. Supply chain disruptions and unforeseen global events can also impact logistics efficiency and reliability Downstream demand is shifting toward higher-value and more globalized applications. The increasing share of innovative biologics is expanding logistics requirements from traditional vaccines to advanced therapies such as cell and gene treatments. The globalization of clinical trials is driving demand for small-batch, high-frequency shipments. Healthcare providers and pharmaceutical companies are raising expectations from simple delivery to full-process quality management, pushing logistics providers to evolve into integrated solution partners. Furthermore, the rise of home-based treatment and decentralized healthcare models is reshaping last-mile delivery requirements.Upstream components primarily include cold chain equipment, temperature-controlled packaging materials, and monitoring technologies. High-performance insulated containers, phase change materials, and dry ice directly impact temperature control performance, while sensors and data loggers ensure traceability throughout the logistics process. With advancements in material science and smart technologies, upstream development is moving toward higher efficiency, intelligence, and sustainability. However, advanced equipment and critical materials still involve significant technological barriers, emphasizing the importance of supply chain reliability.

This report presents a comprehensive overview of the global Biopharmaceutical Logistic market, covering market size and forecast, segmentation by product type and application, competitive landscape, leading players and regional and country-level outlook.

Segment by Type

  • Cold Chain Logistics
  • Non-cold Chain Logistics

Segment by Function

  • Warehousing
  • Transportation
  • Packaging
  • Other

Segment by Product

  • Freight
  • Parcel

Segment by Application

  • Ground Shipping
  • Sea Shipping
  • Air Shipping

Who Can Use This Report?

This report is written for decision-makers who need a clear, data-backed view of the global Biopharmaceutical Logistic market:

  • Manufacturers, suppliers and solution providers benchmarking their position and planning product, capacity and go-to-market strategy
  • Distributors, channel partners and end users in Ground Shipping, Sea Shipping, Air Shipping evaluating demand and sourcing options
  • Investors, financial analysts and consultants assessing growth opportunities, competitive dynamics and M&A potential
  • Government agencies, industry associations and research institutions tracking industry developments and policy impact

Market snapshot

Global Biopharmaceutical Logistic Market Strategic Research Report snapshot, 2025–2032

Source: Market Research Reports
Market size CAGR 8.1%
Regional growth momentum
Market share by segment
Key metrics
Base value
$44.04B
2025
Forecast
$76B
2032
CAGR
8.1%
2025–2032
Régions
5
global
Key companies
Deutsche Post DHLKuehne + NagelUPSMcKessonFedExNippon ExpressCencoraSF Express
© MarketResearchReports.comDisclaimer: The actual data may vary in the final report which undergoes verification check post order confirmation.

Segments covered in this report

By Type
Cold Chain LogisticsNon-cold Chain Logistics
By Application
Ground ShippingSea ShippingAir Shipping

Table of contents

Click a chapter to expand
01Executive Summary
02Industry Overview & Forecast
  • 2.1.1 Market Definition and Scope
  • 2.1.2 Market Size and Growth Forecast
  • 2.1.3 Volume Analysis
  • 2.1.4 Segment Outlook by Type
  • 2.1.5 Segment Outlook by Application
  • 2.1.6 Regional Outlook
  • 2.1.7 Structural Developments Shaping the Forecast
  • 2.1.8 Forecast Risks and Sensitivities
03Market Segmentation by Type
  • 3.1 Market Segmentation by Type
  • 3.1.1 Market by Type Overview
  • 3.1.2 Cold Chain Logistics
  • 3.1.3 Non-cold Chain Logistics
  • 3.1.4 Volume Analysis
04Market Segmentation by Application
  • 4.1 Market Segmentation by Application
  • 4.1.1 Market by Application Overview
  • 4.1.2 Ground Shipping
  • 4.1.3 Sea Shipping
  • 4.1.4 Air Shipping
  • 4.1.5 Volume Analysis
05Regional Market Forecast
  • Asia Pacific
  • North America
  • Europe
  • Middle East & Africa
  • Latin America
06Country-Level Market Forecast
  • 6.1 Asia Pacific
  • 6.1.1 China
  • 6.1.2 Japan
  • 6.1.3 Korea
  • 6.1.4 Southeast Asia
  • 6.1.5 India
  • 6.1.6 Australia
  • 6.1.7 Rest of Asia Pacific
  • 6.2 North America
  • 6.2.1 United States
  • 6.2.2 Canada
  • 6.2.3 Mexico
  • 6.2.4 Rest of North America
  • 6.3 Europe
  • 6.3.1 Germany
  • 6.3.2 France
  • 6.3.3 UK
  • 6.3.4 Italy
  • 6.3.5 Russia
  • 6.3.6 Rest of Europe
  • 6.4 Middle East & Africa
  • 6.4.1 Egypt
  • 6.4.2 South Africa
  • 6.4.3 Israel
  • 6.4.4 Turkey
  • 6.4.5 GCC Countries
  • 6.4.6 Rest of Middle East & Africa
  • 6.5 Latin America
  • 6.5.1 Brazil
  • 6.5.2 Rest of Latin America
07Growth Drivers & Inhibitors
  • 7.1 Growth Drivers & Inhibitors
  • 7.1.1 Section Overview
  • 7.1.2 Growth Drivers
  • 7.1.3 Growth Inhibitors
  • 7.1.4 Driver and Inhibitor Impact Assessment
  • 7.1.5 Analyst Perspective
08Key Company Profiles
  • 8.1 Deutsche Post DHL
  • 8.1.1 Company Overview
  • 8.1.2 Key Products & Segments
  • 8.1.3 Financial Performance (2023–2025)
  • 8.1.4 Business Strategy
  • 8.1.5 SWOT Analysis
  • 8.1.6 Strategic Implications (2026–2032)
  • 8.2 Kuehne + Nagel
  • 8.2.1 Company Overview
  • 8.2.2 Key Products & Segments
  • 8.2.3 Financial Performance (2023–2025)
  • 8.2.4 Business Strategy
  • 8.2.5 SWOT Analysis
  • 8.2.6 Strategic Implications (2026–2032)
  • 8.3 UPS
  • 8.3.1 Company Overview
  • 8.3.2 Key Products & Segments
  • 8.3.3 Financial Performance (2023–2025)
  • 8.3.4 Business Strategy
  • 8.3.5 SWOT Analysis
  • 8.3.6 Strategic Implications (2026–2032)
  • 8.4 McKesson
  • 8.4.1 Company Overview
  • 8.4.2 Key Products & Segments
  • 8.4.3 Financial Performance (2023–2025)
  • 8.4.4 Business Strategy
  • 8.4.5 SWOT Analysis
  • 8.4.6 Strategic Implications (2026–2032)
  • 8.5 FedEx
  • 8.5.1 Company Overview
  • 8.5.2 Key Products & Segments
  • 8.5.3 Financial Performance (2023–2025)
  • 8.5.4 Business Strategy
  • 8.5.5 SWOT Analysis
  • 8.5.6 Strategic Implications (2026–2032)
  • 8.6 Nippon Express
  • 8.6.1 Company Overview
  • 8.6.2 Key Products & Segments
  • 8.6.3 Financial Performance (2023–2025)
  • 8.6.4 Business Strategy
  • 8.6.5 SWOT Analysis
  • 8.6.6 Strategic Implications (2026–2032)
  • 8.7 Cencora
  • 8.7.1 Company Overview
  • 8.7.2 Key Products & Segments
  • 8.7.3 Financial Performance (2023–2025)
  • 8.7.4 Business Strategy
  • 8.7.5 SWOT Analysis
  • 8.7.6 Strategic Implications (2026–2032)
  • 8.8 SF Express
  • 8.8.1 Company Overview
  • 8.8.2 Key Products & Segments
  • 8.8.3 Financial Performance (2023–2025)
  • 8.8.4 Business Strategy
  • 8.8.5 SWOT Analysis
  • 8.8.6 Strategic Implications (2026–2032)
  • 8.9 CMA CGM
  • 8.9.1 Company Overview
  • 8.9.2 Key Products & Segments
  • 8.9.3 Financial Performance (2023–2025)
  • 8.9.4 Business Strategy
  • 8.9.5 SWOT Analysis
  • 8.9.6 Strategic Implications (2026–2032)
  • 8.10 DSV
  • 8.10.1 Company Overview
  • 8.10.2 Key Products & Segments
  • 8.10.3 Financial Performance (2023–2025)
  • 8.10.4 Business Strategy
  • 8.10.5 SWOT Analysis
  • 8.10.6 Strategic Implications (2026–2032)
  • 8.11 Kerry Logistics
  • 8.11.1 Company Overview
  • 8.11.2 Key Products & Segments
  • 8.11.3 Financial Performance (2023–2025)
  • 8.11.4 Business Strategy
  • 8.11.5 SWOT Analysis
  • 8.11.6 Strategic Implications (2026–2032)
  • 8.12 CH Robinson
  • 8.12.1 Company Overview
  • 8.12.2 Key Products & Segments
  • 8.12.3 Financial Performance (2023–2025)
  • 8.12.4 Business Strategy
  • 8.12.5 SWOT Analysis
  • 8.12.6 Strategic Implications (2026–2032)
  • 8.13 Air Canada Cargo
  • 8.13.1 Company Overview
  • 8.13.2 Key Products & Segments
  • 8.13.3 Financial Performance (2023–2025)
  • 8.13.4 Business Strategy
  • 8.13.5 SWOT Analysis
  • 8.13.6 Strategic Implications (2026–2032)
  • 8.14 Sinopharm Group
  • 8.14.1 Company Overview
  • 8.14.2 Key Products & Segments
  • 8.14.3 Financial Performance (2023–2025)
  • 8.14.4 Business Strategy
  • 8.14.5 SWOT Analysis
  • 8.14.6 Strategic Implications (2026–2032)
  • 8.15 Shanghai Pharma
  • 8.15.1 Company Overview
  • 8.15.2 Key Products & Segments
  • 8.15.3 Financial Performance (2023–2025)
  • 8.15.4 Business Strategy
  • 8.15.5 SWOT Analysis
  • 8.15.6 Strategic Implications (2026–2032)
  • 8.16 CR Pharma
  • 8.16.1 Company Overview
  • 8.16.2 Key Products & Segments
  • 8.16.3 Financial Performance (2023–2025)
  • 8.16.4 Business Strategy
  • 8.16.5 SWOT Analysis
  • 8.16.6 Strategic Implications (2026–2032)
  • 8.17 Jointown Logistics
  • 8.17.1 Company Overview
  • 8.17.2 Key Products & Segments
  • 8.17.3 Financial Performance (2023–2025)
  • 8.17.4 Business Strategy
  • 8.17.5 SWOT Analysis
  • 8.17.6 Strategic Implications (2026–2032)
  • 8.18 BioLife Solutions
  • 8.18.1 Company Overview
  • 8.18.2 Key Products & Segments
  • 8.18.3 Financial Performance (2023–2025)
  • 8.18.4 Business Strategy
  • 8.18.5 SWOT Analysis
  • 8.18.6 Strategic Implications (2026–2032)
  • 8.19 OOCL Logistics
  • 8.19.1 Company Overview
  • 8.19.2 Key Products & Segments
  • 8.19.3 Financial Performance (2023–2025)
  • 8.19.4 Business Strategy
  • 8.19.5 SWOT Analysis
  • 8.19.6 Strategic Implications (2026–2032)
  • 8.20 Shengsheng Pharmaceutical Cold Chain
  • 8.20.1 Company Overview
  • 8.20.2 Key Products & Segments
  • 8.20.3 Financial Performance (2023–2025)
  • 8.20.4 Business Strategy
  • 8.20.5 SWOT Analysis
  • 8.20.6 Strategic Implications (2026–2032)
09Competitive Landscape
  • 9.1 Competitive Landscape Overview
  • 9.2 Competitive Intensity Assessment
  • 9.3 Key Player Strategies & Positioning
  • 9.4 Competitive Dynamics & Strategic Outlook
  • 9.4.1 Emerging Competitive Threats
  • 9.4.2 Consolidation vs. Fragmentation Outlook
  • 9.4.3 Competitive Response Matrix
  • 9.4.4 Strategic Recommendations, 2026–2032
10Porter's Five Forces Analysis
  • 10.1 Threat of New Entrants
  • 10.2 Bargaining Power of Buyers
  • 10.3 Bargaining Power of Suppliers
  • 10.4 Threat of Substitutes
  • 10.5 Competitive Rivalry
11PESTLE Analysis
  • 11.1 Political
  • 11.2 Economic
  • 11.3 Social and Demographic
  • 11.4 Technological
  • 11.5 Legal and Regulatory
  • 11.6 Environmental
  • 11.7 Strategic Implications of the PESTLE Assessment
12SWOT Analysis
13Future Trends & Outlook
  • 13.1 Future Trends & Outlook
  • 13.1.1 Trend Summary and Commercial Maturity Assessment
  • 13.1.2 Technology and Innovation Trends
  • 13.1.3 Long-Term Market Outlook
  • 13.1.4 Investment & M&A Activity Outlook
  • 13.1.5 Overall Outlook Assessment

Frequently asked questions

What is the size of the global Biopharmaceutical Logistic market?
The global Biopharmaceutical Logistic market is estimated at US$ 44.04 billion in 2025 (base year) and is projected to reach US$ 76.07 billion by 2032.
What is the forecast CAGR for the Biopharmaceutical Logistic market?
The market is expected to grow at a CAGR of 8.1% from 2026 to 2032, expanding from US$ 44.04 billion in 2025 to US$ 76.07 billion in 2032, roughly 1.7 times its base-year value.
What is Biopharmaceutical Logistic?
Biopharmaceutical Logistics refers to a specialized logistics system that manages temperature-controlled transportation, storage, and supply chain coordination throughout the entire lifecycle of biopharmaceutical products, including development, manufacturing, distribution, and clinical use. Its primary objective is to ensure the integrity, safety, and regulatory compliance of high-value biologics such as vaccines, monoclonal antibodies, and cell and gene therapies.
How is the Biopharmaceutical Logistic market segmented by type?
By type, the market is segmented into Cold Chain Logistics and Non-cold Chain Logistics.
What are the key applications of Biopharmaceutical Logistic?
Key applications covered include Ground Shipping, Sea Shipping and Air Shipping.
Which companies are profiled in the Biopharmaceutical Logistic market report?
Key players profiled include Deutsche Post DHL, Kuehne + Nagel, UPS, McKesson, FedEx, Nippon Express, Cencora and SF Express, among 20 companies covered in total.
What geographies does the Biopharmaceutical Logistic market analysis include?
The market is analysed across Asia Pacific, North America, Europe, Middle East & Africa and Latin America, with 20 country-level markets including China, Japan, United States, Canada, Germany, France, Egypt and South Africa.
What are the key demand drivers for Biopharmaceutical Logistic?
Driven by the rapid expansion of the global biopharmaceutical industry and the accelerated commercialization of innovative therapies, biopharmaceutical logistics is experiencing strong structural growth.
What are the main risks and barriers in the Biopharmaceutical Logistic market?
Meanwhile, the integration of digital technologies and IoT is enhancing visibility and traceability across the supply chain, further elevating industry value.Despite strong growth prospects, the industry faces several challenges.
Who should buy the Biopharmaceutical Logistic market report?
The report is intended for manufacturers and solution providers, distributors and end users in Ground Shipping, Sea Shipping and Air Shipping, investors and consultants, and government or industry bodies who need market size, segmentation, competitive and regional data for the Biopharmaceutical Logistic market.
What license options are available for this report?
The report is available as a Single User License (US$ 3,500, one named user), a Site License (US$ 5,250, up to 10 users) and a Global / Corporate License (US$ 7,000, unlimited users), all delivered in PDF format.

Research Methodology

All MarketResearchReports.com strategic research reports follow a rigorous, multi-stage methodology combining AI-assisted data synthesis with expert analyst validation.

01
Secondary Research & Data Aggregation

Systematic collection from 500+ verified sources including SEC filings, industry databases (Bloomberg, Statista, OECD), regulatory filings, trade publications, patent databases, and company annual reports. AI-assisted extraction identifies relevant data points across 10,000+ documents per report.

02
Market Sizing — Bottom-Up & Top-Down

Dual-validation approach: bottom-up sizing aggregates segment-level production, consumption, and trade data; top-down sizing cross-validates against macroeconomic indicators and total addressable market estimates. Discrepancies >5% trigger analyst review.

03
Competitive Intelligence

Company profiles built from public financial disclosures, product launches, M&A activity, job postings (as capability proxies), and supply chain mapping. Market share estimates triangulated across revenue, capacity, and shipment data.

04
Demand Forecasting

CAGR projections use time-series regression on 5-10 years of historical data, adjusted for identified demand drivers (technology adoption curves, regulatory catalysts, demographic shifts) and demand inhibitors (cost barriers, substitution risk). Scenario modeling covers base, optimistic, and conservative cases.

05
Analyst Validation & Quality Assurance

All quantitative outputs reviewed by a domain-specialist analyst before publication. Data triangulation requires minimum 3 independent sources for every key figure. Reports undergo a structured peer review against our 47-point quality checklist covering methodology, data citations, logical consistency, and formatting standards.

06
Continuous Updates

On-demand reports are generated at time of purchase, incorporating the most recent available data. Static reports are republished when underlying market conditions shift by >10% from baseline assumptions. Purchasers receive update notifications for 12 months.

Select a license
from 3 500,00 $US
Report License Type
Optional add-ons
On demand · delivered within 24-48 hours
Secure checkout · SSL encrypted
License terms included
Post-purchase analyst support
Custom research

Need a customized version?

Get country-, segment- or company-specific intelligence tailored to your exact requirements.

Request custom research →
Talk to a research advisor USA: +1-302-703-9904 India: +91-8762746600
Trusted by

Leading Brands in This Industry

Logos are trademarks of their respective owners and indicate a verified past business relationship, not a current partnership or endorsement.